These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2044 related items for PubMed ID: 12375059

  • 1. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R, Lees AJ.
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [Abstract] [Full Text] [Related]

  • 2. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.
    Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ, Parkinson's Disease Research Group of the United Kingdom.
    Neurology; 2008 Aug 12; 71(7):474-80. PubMed ID: 18579806
    [Abstract] [Full Text] [Related]

  • 3. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P, Tremblay L, Féger J, Hirsch EC.
    Rev Neurol (Paris); 2000 Mar 12; 156(3):224-35. PubMed ID: 10740093
    [Abstract] [Full Text] [Related]

  • 4. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F, Lilliu H, Le Pen C.
    Rev Neurol (Paris); 2001 May 12; 157(5):507-14. PubMed ID: 11438770
    [Abstract] [Full Text] [Related]

  • 5. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A, Parkinson Study Group.
    Arch Neurol; 2004 Jul 12; 61(7):1044-53. PubMed ID: 15262734
    [Abstract] [Full Text] [Related]

  • 6. Levodopa in the early treatment of Parkinson's disease.
    Murata M.
    Parkinsonism Relat Disord; 2009 Jan 12; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [Abstract] [Full Text] [Related]

  • 7. Drug-induced motor complications in dopa-responsive dystonia: implications for the pathogenesis of dyskinesias and motor fluctuations.
    de la Fuente-Fernández R.
    Clin Neuropharmacol; 1999 Jan 12; 22(4):216-9. PubMed ID: 10442251
    [Abstract] [Full Text] [Related]

  • 8. Role of dopamine receptor agonists in the treatment of early Parkinson's disease.
    Bonuccelli U, Del Dotto P, Rascol O.
    Parkinsonism Relat Disord; 2009 Dec 12; 15 Suppl 4():S44-53. PubMed ID: 20123557
    [Abstract] [Full Text] [Related]

  • 9. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF, Gao J, Durairajan SS, Man SC, Xie LX, Lu JH, Fong WL, Li M.
    J Clin Neurosci; 2009 Aug 12; 16(8):1034-7. PubMed ID: 19428256
    [Abstract] [Full Text] [Related]

  • 10. [Current preclinical findings on substances against Parkinson's disease].
    Gerlach M, Riederer P.
    Nervenarzt; 2003 Mar 12; 74 Suppl 1():S2-6. PubMed ID: 12624677
    [Abstract] [Full Text] [Related]

  • 11. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, Watt H, Bhatia K, Quinn N, Lees AJ.
    Mov Disord; 2005 Feb 12; 20(2):151-7. PubMed ID: 15390035
    [Abstract] [Full Text] [Related]

  • 12. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH, Klasser M, Reichmann H.
    Fortschr Neurol Psychiatr; 2008 Oct 12; 76(10):594-9. PubMed ID: 18833504
    [Abstract] [Full Text] [Related]

  • 13. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.
    Int J Clin Pract; 2009 Apr 12; 63(4):613-23. PubMed ID: 19222614
    [Abstract] [Full Text] [Related]

  • 14. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Fox SH, Chuang R, Brotchie JM.
    Prog Brain Res; 2008 Apr 12; 172():479-94. PubMed ID: 18772047
    [Abstract] [Full Text] [Related]

  • 15. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years.
    Hely MA, Morris JG, Reid WG, Trafficante R.
    Mov Disord; 2005 Feb 12; 20(2):190-9. PubMed ID: 15551331
    [Abstract] [Full Text] [Related]

  • 16. [Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe Parkinsonian's patients].
    Vaamonde J, Ibáñez R, Gudín M, Hernández A.
    Neurologia; 2003 Apr 12; 18(3):162-5. PubMed ID: 12677484
    [Abstract] [Full Text] [Related]

  • 17. [Advances in the medical treatment of Parkinson's disease].
    Chaná P.
    Parkinsonism Relat Disord; 2009 Dec 12; 15 Suppl 3():S22-5. PubMed ID: 20082996
    [Abstract] [Full Text] [Related]

  • 18. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
    Picconi B, Paillé V, Ghiglieri V, Bagetta V, Barone I, Lindgren HS, Bernardi G, Angela Cenci M, Calabresi P.
    Neurobiol Dis; 2008 Feb 12; 29(2):327-35. PubMed ID: 17997101
    [Abstract] [Full Text] [Related]

  • 19. Levodopa delivery systems: advancements in delivery of the gold standard.
    Ngwuluka N, Pillay V, Du Toit LC, Ndesendo V, Choonara Y, Modi G, Naidoo D.
    Expert Opin Drug Deliv; 2010 Feb 12; 7(2):203-24. PubMed ID: 20095943
    [Abstract] [Full Text] [Related]

  • 20. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK, Banerji T, Jenner P, Marsden CD.
    Mov Disord; 1998 Mar 12; 13(2):234-41. PubMed ID: 9539335
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 103.